Cancer Institute A national cancer institute
designated cancer center

Tumor Heterogeneity: Implications for Targeted Therapy

October 6 - 7, 2014
Li Ka Shing Center for Learning & Knowledge

Sponsored by the Stanford Cancer Institute

There has been great hope that "targeted therapies," honing in on specific molecular defects, could revolutionize cancer treatment.  However, the inconsistent performance of targeted therapies, and new measurements highlighting the heterogeneity of cancer cells within individual patients, has raised critical questions about therapeutic strategies.  This symposium will address how our evolving understanding of intra-patient heterogeneity will affect basic research, translational research and clinical cancer care.

This symposium should be of interest to physicians practicing all subspecialties of oncology, as well as professionals involved in human genetics, genetic counseling, and molecularly-based clinical trials design and implementation.  Material should also be of fundamental interest to basic and translational researchers involved in using tumor omics to understanding tumor development, progression and prognosis in personalized cancer treatment.  The content will directly affect on how researchers and physicians characterize tumors leading to better choice of therapies and monitoring of response.

Read SCI director Beverly Mitchell's commentary on intra-tumor heterogeneity in The Scientist.

Registration is now open!

Program

Abstract Submissions

 

Logistical Information:

Li Ka Shing Center for Learning & Knowledge

Directions & Parking

Local Hotels:

Rosewood Sand Hill Hotel

Stanford Park Hotel

Sheraton Palo Alto

The Westin Palo Alto

 

 

 


 

Stanford Medicine Resources:

Footer Links: